List view / Grid view
11 May 2015 | By Victoria White
Novogen, in conjunction with Australian paediatric cancer researchers, released key preclinical data on experimental cancer drug-candidate, TRXE-009...
7 May 2015 | By Victoria White
Plexxikon and MSD have announced a collaborative clinical trial that will evaluate the combination of PLX3397 and KEYTRUDA in melanoma...
6 May 2015 | By Victoria White
Scientists at The Institute of Cancer Research have found that ROCK inhibitors dramatically reduced the ability of melanoma cells to move through tissue...
23 April 2015 | By Victoria White
An article describing an important scientific foundation for the clinical development of truly personalised cancer immunotherapies has been published...
17 April 2015 | By Victoria White
Novogen and the Feinstein Institute for Medical Research are to collaborate to develop effective treatments for brain cancers...
9 April 2015 | By Victoria White
Novogen has announced that studies conducted at UQDI revealed that experimental drug Anisina killed melanoma cells irrespective of their mutational status...
1 April 2015 | By Victoria White
A consortium will collaborate with Basilea to progress a new family of cancer drugs designed to block several key cancer-causing proteins at once...
11 March 2015 | By MRC Technology
New breakthrough immunotherapy (pembrolizumab) launched in the UK for treatment of adults with advanced melanoma...
26 February 2015 | By Roche
Contribution to the treatment of melanoma by personalized healthcare...
6 January 2015 | By The Institute of Cancer Research
An experimental cancer drug may block an important driver for the survival, growth and spread of cancer cells...
15 December 2014 | By The Institute of Cancer Research, London, and Cancer Research UK Manchester Institute
A brand new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers, a major new study reports...
24 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb and Five Prime Therapeutics have announced exclusive clinical collaboration to evaluate the combination of investigational immunotherapies Opdivo (nivolumab) and FPA008 in six tumor types...
14 October 2014 | By Rigontec GmbH
Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the first closing of its Series A financing round, raising €9.45 million...
3 October 2014 | By OBN
OBN revealed last night the winners of its Annual Awards celebrating the best of UK life sciences – the innovators, fundraisers and dealmakers who underline the pre-eminence of the UK sector in the global marketplace...
16 September 2014 | By Andrew Lloyd & Associates
Curie-Cancer and Inventiva announce the launch of the Epicure project, which has just received financial backing from France’s national research agency, the ANR...
